- Home
- GENK vs NXL Comparison
GENK vs NXL Comparison
Compare GENK & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENK
- NXL
- Stock Information
- Founded
- GENK 2011
- NXL 2010
- Country
- GENK United States
- NXL United States
- Employees
- GENK N/A
- NXL N/A
- Industry
- GENK Restaurants
- NXL Medical Specialities
- Sector
- GENK Consumer Discretionary
- NXL Health Care
- Exchange
- GENK Nasdaq
- NXL Nasdaq
- Market Cap
- GENK 16.3M
- NXL 17.8M
- IPO Year
- GENK 2023
- NXL 2022
- Fundamental
- Price
- GENK $3.03
- NXL $1.52
- Analyst Decision
- GENK Strong Buy
- NXL Strong Buy
- Analyst Count
- GENK 2
- NXL 1
- Target Price
- GENK $7.00
- NXL $5.00
- AVG Volume (30 Days)
- GENK 75.2K
- NXL 10.4M
- Earning Date
- GENK 11-11-2025
- NXL 11-07-2025
- Dividend Yield
- GENK 3.95%
- NXL N/A
- EPS Growth
- GENK N/A
- NXL N/A
- EPS
- GENK N/A
- NXL N/A
- Revenue
- GENK $216,137,000.00
- NXL $174,813.00
- Revenue This Year
- GENK $12.35
- NXL $38.28
- Revenue Next Year
- GENK $14.62
- NXL $185.71
- P/E Ratio
- GENK N/A
- NXL N/A
- Revenue Growth
- GENK 10.67
- NXL 16.42
- 52 Week Low
- GENK $2.65
- NXL $0.70
- 52 Week High
- GENK $10.33
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- GENK 49.45
- NXL 61.70
- Support Level
- GENK $2.90
- NXL $1.20
- Resistance Level
- GENK $3.15
- NXL $1.46
- Average True Range (ATR)
- GENK 0.17
- NXL 0.17
- MACD
- GENK 0.03
- NXL 0.04
- Stochastic Oscillator
- GENK 66.96
- NXL 57.89
About GENK GEN Restaurant Group Inc.
GEN Restaurant Group Inc operates an Asian casual dining restaurant chain, offering an extensive menu of traditional Korean and Korean-American food, including high-quality meats, poultry, seafood, and mixed vegetables. It operates 43 Gen Korean BBQ restaurants in the United States.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.